Three new grants totaling $1.44 million will support innovative approaches to cancer immunotherapy, advancing research with potential implications for both cancer treatment and HIV cure science
- The grants awarded go to Drs. Omar Abdel-Wahab of Memorial Sloan Kettering Cancer Center, Ekaterina Vinogradova of The Rockefeller University, and Francesca Granucci of the University of Milano-Bicocca
- Two projects will investigate new ways to overcome T cell exhaustion, in which immune cells lose their ability to effectively fight disease, while the third explores ways to make tumors more susceptible to attack by the immune system
- Each investigator will receive $480,000 over a period of two years
NEW YORK, November 19, 2026 — Building on its more than 40-year history of scientific discovery to advance the prevention, treatment, and eventual cure of HIV, amfAR is applying its unique approach of support for untested ideas with breakthrough potential to a wider spectrum of biomedical research.
Today, amfAR announced its first-ever investment in cancer research, awarding $1.44 million to three innovative projects exploring new ways to harness the immune system to fight cancer. Marking a significant expansion of amfAR’s research mission, the grants represent an initial and critical step in the organization’s commitment to investing in research aimed at improving global health through a focus on accessibility, affordability, and scalability.
“For four decades, amfAR has backed bold ideas that have helped transform the lives of millions of people living with HIV,” amfAR CEO Kyle Clifford said. “The knowledge and approaches developed through HIV research have opened new doors and changed medicine. Covid vaccines, cancer immunotherapies, and the idea of person-first healthcare all sprung out of the response to the HIV epidemic.
“This investment represents an exciting new chapter for amfAR to accelerate discoveries that can benefit people affected by HIV, cancer, and other diseases and conditions, while reaffirming our deeply held commitment to curing HIV,” Clifford continued.
All three projects selected for funding focus on strengthening the immune system’s ability to recognize and eliminate problematic cells, and knowledge gained through these studies can be applied not only to tumors, but also potentially to HIV that persists in a reservoir of infected cells beyond the reach of antiretroviral therapy and forming the primary barrier to a cure.
Two of the three will investigate ways to overcome T cell exhaustion, in which immune cells lose their ability to target diseased cells over time. This is not only relevant to cancer treatment, but also to HIV cure research, where scientists are exploring new ways to improve the immune system’s ability to identify and eliminate the HIV reservoir.
“What excites us about these three researchers’ projects in particular is they build on existing knowledge and developing new approaches to circumvent current limitations in the ability of our immune systems to control cancer,” amfAR Vice President of Research Dr. Andrea Gramatica said. “One of the most compelling connections between cancer and HIV research is that both involve targeting cells of our own body, be they tumors or the HIV reservoir. Developing ways to selectively recognize and eliminate these cells while sparing healthy tissue is a challenge shared by both fields, and breakthroughs in one can help accelerate progress in the other.”
Omar Abdel-Wahab, MD, of Memorial Sloan Kettering Cancer Center in New York has identified a unique form of RNA in exhausted T cells. With amfAR funding, Dr. Abdel-Wahab will use this discovery to engineer immune cells that can activate protective genes or release immune-boosting molecules when they begin to lose function. He and his team will test this approach using several types of engineered T cells, including CAR T cells, to determine whether they can overcome exhaustion, improve tumor clearance, and minimize harmful side effects. If successful, this work could lead to new immunotherapies capable of sustaining T cell activity and improving the body’s ability to eliminate tumors.
Ekaterina Vinogradova, PhD, of The Rockefeller University in New York, will also investigate ways to overcome T cell exhaustion. Using advanced tools developed in her lab, Dr. Vinogradova will identify previously inaccessible sites on proteins that have been discovered to regulate T cell exhaustion and screen for small molecules that can effectively bind to them. She and her team will test the most promising targets and compounds for their ability to restore T cell function. If successful, this research could lead to a new generation of drugs that can overcome T cell exhaustion, potentially making existing immunotherapies more effective and longer-lasting.
Lastly, Francesca Granucci, PhD, of the University of Milano-Bicocca in Italy, will investigate whether temporarily reprogramming tumor cells can make them more susceptible to attack by the immune system. Immune checkpoint blockade therapies have transformed cancer treatment, helping the immune system recognize and attack tumors. However, some tumors develop ways to evade immune attack, limiting the efficacy of these therapies. Dr. Granucci and her team will use nanoparticles to alter the behavior of cancer cells, prompting them to attract greater numbers of cancer-fighting immune cells. They will then investigate whether carefully timed intervention can improve responses to immune checkpoint blockade. If successful, this research could establish a new approach to making tumors more responsive to existing immunotherapies, potentially extending their benefits to patients whose cancers have historically been more resistant to treatment.
These new grants reflect amfAR’s belief that supporting ambitious research can produce results beyond the fields in which the initial studies were conducted.
Together, these three projects represent the beginning of an expanded approach to amfAR’s research investments, improving global health by providing critical early-stage funding to transformative ideas, particularly across conditions where viruses and the immune system play an important role, as with HIV.
About amfAR
amfAR is a leading nonprofit dedicated to advancing scientific discovery and transforming global health with a primary and enduring commitment to ending the HIV/ AIDS epidemic. Serving as a catalyst for breakthrough science, amfAR supports innovative research in areas where viruses and the immune system play a defining role, including cancer, neurological conditions, autoimmune disorders, and other viral diseases. Through strategic investments, global research partnerships, and evidence-based policy leadership, amfAR helps accelerate discoveries that improve health and save lives. Since 1985, amfAR has raised more than $950 million and awarded in excess of 3,900 grants to scientists worldwide. Learn more at www.amfar.org.
Media Contact:
Robert Kessler; Associate Director, Program Communications
(212) 806-1602
robert.kessler@amfar.org


